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Abstract  
Background 
Fatigue is one of the most commonly reported and debilitating symptoms of multiple 
sclerosis (MS); approximately two-thirds of people with MS consider it to be one of 
their three most troubling symptoms. It may limit or prevent participation in everyday 
activities, work, leisure, and social pursuits, reduce psychological well-being and is 
one of the key precipitants of early retirement. Energy effectiveness approaches have 
been shown to be effective in reducing MS-fatigue, increasing self-efficacy and 
improving quality of life. Cognitive behavioural approaches have been found to be 
effective for managing fatigue in other conditions, such as chronic fatigue syndrome, 
and more recently, in MS. The aim of this pragmatic trial is to evaluate the clinical 
and cost-effectiveness of a recently developed group-based fatigue management 
intervention (that blends cognitive behavioural and energy effectiveness approaches) 
compared with current local practice.  
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Methods/Design 
This is a multi-centre parallel arm block-randomised controlled trial (RCT) of a six 
session group-based fatigue management intervention, delivered by health 
professionals, compared with current local practice. 180 consenting adults with a 
confirmed diagnosis of MS and significant fatigue levels, recruited via 
secondary/primary care or newsletters/websites, will be randomised to receive the 
fatigue management intervention or current local practice. An economic evaluation 
will be undertaken alongside the trial. Primary outcomes are fatigue severity, self-
efficacy and disease-specific quality of life. Secondary outcomes include fatigue 
impact, general quality of life, mood, activity patterns, and cost-effectiveness. 
Outcomes in those receiving the fatigue management intervention will be measured 1 
week prior to, and 1, 4, and 12 months after the intervention (and at equivalent times 
in those receiving current local practice). A qualitative component will examine what 
aspects of the fatigue management intervention participants found helpful/unhelpful 
and barriers to change.  
 
Discussion 
This trial is the fourth stage of a research programme that has followed the Medical 
Research Council guidance for developing and evaluating complex interventions. 
What makes the intervention unique is that it blends cognitive behavioural and energy 
effectiveness approaches. A potential strength of the intervention is that it could be 
integrated into existing service delivery models as it has been designed to be delivered 
by staff already working with people with MS. Service users will be involved 
throughout this research. 
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Trial registration: Current Controlled Trials ISRCTN76517470 
Background  
 Multiple sclerosis (MS) is a chronic, unpredictable, incurable, demyelinating disease 
of the central nervous system affecting approximately 2.5 million people [1-3]. It is 
more common in women and onset peaks between 20 and 40 years. The causes and 
early development of the disease are not fully understood but probably involve 
immune, genetic, and environmental factors [2,3]. Fatigue is one of the most 
commonly reported and disabling symptoms of MS, often occurring daily [4] and 
with a variable course [5,6]. Up to 86% of individuals with MS experience fatigue at 
any one time; 65% consider it to be one of their three most troubling symptoms [4].  
 
Fatigue has been defined as a “subjective lack of physical and/or mental energy that is 
perceived by the individual or caregiver to interfere with usual or desired activities, p. 
2’’ [7]. The pathophysiology of fatigue is unclear [8] but likely to be multi-factorial 
[9,10]. Findings on the relationships between fatigue and other clinical variables (such 
as age, gender, disease duration, and clinical activity) have been equivocal [11]. 
  
Researchers have distinguished between primary and secondary fatigue [12]. 
‘Primary’ fatigue relates to aspects of fatigue deemed to be directly related to the 
disease process such as lassitude or asthenia (an overwhelming sense of tiredness not 
directly related to participation in activity or exercise), ‘short-circuiting’ fatigue 
(when muscular performance deteriorates during sustained activity but recovers after 
a short rest break) and heat sensitive fatigue (where fatigue is triggered or worsened 
by heat). 
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‘Secondary’ fatigue refers to fatigue that is not unique to MS and is related to factors 
common to a range of chronic and disabling conditions (e.g. sleep disturbance, 
medication side effects, infection, physical exertion, depression, anxiety, stressful life 
events, characteristics of the local environment - such as lighting and temperature 
within a work setting). The relationship between these dimensions is complex; various 
symptoms of MS may act as predisposing factors for secondary fatigue. 
 
Fatigue may limit or prevent participation in everyday activities, work, leisure and 
social pursuits, restrict role fulfilment and reduce psychological well-being [12,13] 
and is one of the key precipitants of early retirement [14,15]. Its ‘invisible’ nature 
may lead to difficulties in personal and work relationships [16,17].  
 
Fatigue is highly related to an individual’s sense of control over MS and 
psychological well-being [13,18,19]. Sense of control has been found to predict lower 
levels of fatigue [20], suggesting that increasing self-efficacy related to fatigue could 
improve quality of life.  
 
Pharmacological and non-pharmacological treatments are available for MS-related 
fatigue, but evidence on effectiveness is mostly inconclusive or non-existent 
[4,21,22]. Non-pharmacological studies exploring the effectiveness of energy 
conservation programmes for MS-fatigue have tended to be small and uncontrolled 
[23-27]. Two fatigue management initiatives have been developed in the UK [28,29]. 
Only the former has been evaluated and numbers were small. In the USA, a 
randomised controlled trial (RCT) [30] of an energy conservation course [31] found 
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evidence for its effectiveness in reducing fatigue impact, increasing self-efficacy and 
aspects of quality of life; benefits were maintained at 1 year [32]. Results from a 
German adaptation were also promising [33]. A RCT that evaluated a multi-
disciplinary fatigue management programme [34] demonstrated no reduction in 
fatigue impact compared with a placebo intervention.  
 
Although the important relationships between physical and psychological aspects of 
MS-fatigue are recognised [35], high quality RCTs of psychological interventions are 
rare [36]. In Chronic Fatigue Syndrome (CFS) individual Cognitive Behavioural 
Therapy (CBT) is effective in treating fatigue [37,38]. A systematic review [39] of 
psychological interventions for MS identified just one RCT that used a cognitive 
behavioural approach to manage MS-fatigue [40]. The intervention consisted of 
individual CBT conducted by a clinical psychologist and was shown to be effective in 
reducing fatigue. However, in the UK National Health Service (NHS), and elsewhere, 
psychologists working with people with MS are scarce, thus this approach may prove 
impractical [39].  
 
A number of pilot studies have used group-based cognitive behavioural approaches, 
either in the context of coping with MS [41-43], or specifically with MS-fatigue [44]. 
Group-based approaches are potentially more cost effective than one-to-one and offer 
opportunities for peer support. Recently, we have developed a group-based 
manualised fatigue intervention for the management of MS fatigue that incorporates 
energy effectiveness and cognitive behavioural approaches [45]. This intervention 
involves health professionals routinely involved in the management of MS, supported 
by clinical psychologists, and is thus compatible with a wide range of existing health 
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service structures (such as the UK National Health Service (NHS)). Pilot work has 
been encouraging and this trial is a formal evaluation of the effectiveness of the 
intervention [45]. 
 
Aims 
Patient population: Adults with multiple sclerosis experiencing significant fatigue that 
is impacting on daily life. 
 
Primary aim 
1. To test whether those allocated to the group-based cognitive behavioural fatigue 
management intervention differ (in terms of fatigue severity, self-efficacy, and MS-
specific quality of life) from those allocated to current local practice. 
 
Secondary aims 
2. To test whether those allocated to a group-based cognitive behavioural fatigue 
management intervention differ (in terms of fatigue impact, mood, general quality of 
life, and activity patterns) from those allocated to current local practice. 
 
3. To assess how the group-based cognitive behavioural intervention and current local 
practice differ in terms of cost-effectiveness. 
 
4. For those who attend the group-based programme, to gather feedback about 
experiences of attending the programme, any changes made and barriers to change 
encountered, and helpful or unhelpful aspects.  
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Methods/Design 
Trial design 
This is a parallel arm randomised controlled trial comparing a group-based cognitive 
behavioural approach to managing fatigue (Fatigue Management Programme (FMP)) 
with current local practice. The trial design is summarised in Figure 1. 
 
This RCT is the fourth stage of a research programme that has followed the Medical 
Research Council (MRC) guidance for developing and evaluating complex 
interventions [46]. The pilot work has been published [45].  
 
Participants will be randomised to receive the fatigue management intervention or 
current local practice. A placebo arm to the trial was considered but rejected because 
(a) the fatigue management programme is a “complex intervention” (incorporating 
group, educational, cognitive, behavioural, and energy effectiveness components and 
the attendance of supportive others) making it difficult to know which “active 
ingredients” to control for in the placebo; (b) of the difficulties inherent in designing a 
placebo intervention that is credible to participants and facilitators, and that maintains 
participant masking, and (c) in clinical practice, the costs of delivering the fatigue 
management programme and the sham intervention would be equivalent. 
 
The pilot research (multi-centre pilot) undertaken identified practical difficulties 
involved in running a three centre randomised trial. The multi-centre approach for the 
randomised trial will help to ensure sufficient numbers of participants are recruited 
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and that results are generalisable outside Poole, where the intervention was 
developed.  
 
Setting 
The trial is taking place in three centres (Poole, Bristol, Southampton/Portsmouth) 
and each centre has a team of trained facilitators to deliver the fatigue management 
programme. 
 
Ethical, governance and management considerations 
This trial has been reviewed and given a favourable opinion by the North Somerset 
and South Bristol Multi-Centre Research Ethics Committee (ref: 08/H0106/2). Poole 
Hospital NHS Foundation Trust is acting as sponsor. The study is funded by a project 
grant awarded by the Multiple Sclerosis Society of Great Britain and Northern 
Ireland. The study is included in the National Institute of Health Research Clinical 
Research Network (NIHR CRN) portfolio (ID 4843). 
 
As the trial involves people with MS and fatigue, careful consideration will be given 
to the location of the intervention (e.g. public transportation, car parking, walking 
distances), and the comfort of the participants (room temperature, refreshment breaks, 
cushioned chairs etc.). Because participants will have fatigue, the length of sessions in 
the fatigue management programme has been kept reasonably short, and the number 
and length of outcome measures have been kept to a minimum. Two facilitators will 
run each session. If someone becomes emotionally upset or unwell during a session, 
one of the facilitators can take that person aside, and provide information regarding 
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help and support available from local MS services (such as a MS Specialist Nurse), 
the MS Society and MS Trust, and primary care (General Practice, counselling 
services etc.).  
 
A trial steering group will meet at regular intervals throughout the trial. 
 
Service user support 
There has been service user involvement in all stages of the research so far, including 
the development of this protocol. Service users will be represented on the trial 
steering group. 
 
Data protection 
All information that is collected will be kept strictly confidential and any information 
that leaves Poole Hospital will not contain any personal details. Questionnaires will 
be allocated a participant identification number; they will not contain any names or 
identifying details. Only the authorised members of the research team will have 
access to the trial data. 
 
Participants 
Sample size  
Sample size consideration is mostly based upon fatigue as the primary outcome 
measure; this is the outcome measure used most frequently in other trials that include 
people with fatigue. As a variety of fatigue measures have been used in other trials, 
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we have used standardised effect sizes to enable comparisons between them. 
Standardised effect sizes of 0.2 are commonly considered small, 0.5 considered 
medium, and 0.8 considered large [47]. In this trial, we will aim to detect a medium 
effect size. The Cochrane systematic review of cognitive behavioural therapy in 
people with CFS [38] identified two good quality studies, and in these the 
standardised effect sizes for fatigue were 0.7 and 1.0. The Cochrane Systematic 
Review of Amantadine for fatigue in MS found effect sizes of between 0.3 and 1.4 for 
the three studies that measured fatigue on a continuous scale [21]. Thus, our choice of 
an effect size seems reasonable in the context of (a) how well cognitive behavioural 
approaches work in another chronic disease where fatigue is a major symptom, and 
(b) how well another treatment for fatigue works in MS. For 85% power, the sample 
size requirement (using a two-tailed 5% significance level) is 73 people per arm of the 
trial; 146 in total. Inevitably, there will be some participants who withdraw from the 
trial during its course, or more generally, do not complete outcome measures. To 
allow for this, we will aim to enrol 180 participants; 90 in each arm of the trial. Thus, 
if 20% of participants do not provide data on the primary outcome measures, the 
study would maintain statistical power. This figure of 20% will be reviewed during 
the study and sample size adjusted up or down accordingly.  
 
Eligibility criteria 
Inclusion criteria:  
1. Providing written informed consent.  
2. Over the age of 18.  
3. Clinical diagnosis of relapsing-remitting or progressive multiple sclerosis 
(Poser/McDonald criteria [48-50]. 
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4. Score on the Fatigue Severity Scale (FSS) [51] greater than 4. The FSS is a 
uni-dimensional self-report measure consisting of 9 items that ask about 
severity of fatigue related to daily activities (such as physical functioning, 
exercise, work, family, and social life). Responses are made on a 7-point 
Likert-type scale.  
5. Ambulatory (score on the Adapted Patient Determined Disease Steps 
(APDDS) Scale [52] <8). This self-administered instrument is based on the 
Patient-Determined Disease Steps (PDDS) scale and the telephone Expanded 
Disability Status Scale (EDSS). The programme content will be most relevant 
for those who are ambulatory. Individuals who are non-ambulatory will 
continue to receive standard care.  
6. Able to attend the intervention sessions.  
7. English speaking. 
 
Exclusion criteria:  
1. Attended a specific fatigue management programme within the last year. 
 
2. Received a substantive, specific, fatigue intervention from an Occupational 
Therapist (OT) or other health professional, consisting of more than general advice, 
within the previous 3 months (such as the guidance produced by the National 
Association of Neurological Occupational Therapists (NANOT) [53] (now known as 
the College of Occupational Therapists Specialist Section - Neurological Practice) 
[29]. 
 
3. Already involved in another research study. 
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4. Individuals who have cognitive deficits such that they would not be able to engage 
in the group format or benefit from the programme. If individuals have substantial 
cognitive deficits much of the content of the fatigue management programme would 
not be appropriate. This will be based on the judgement of health professionals/local 
investigators.  
 
5. Individuals who have had a relapse within the previous three months. This would 
be a potential confound since a change in fatigue could be the result of treatment or 
improvement after a recent relapse. 
 
6. Individuals who have been on a disease-modifying drug (such as Beta-Interferon, 
Glatiramer Acetate) or an anti-depressant for fewer than 3 months. One of the 
possible initial side effects of these drugs is fatigue and thus this could be a 
confounder.  
 
7. Individuals who are known to be currently under the care of a psychiatrist or under 
the care of addiction services will be excluded. Ongoing psychiatric disorders or 
addiction problems would compromise the potential to benefit from the programme. 
 
Individuals excluded from the research project will continue to be seen as per usual 
care.  
 
Source of participants 
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The recruitment target for each of the three centres will be 60 people, of whom 30 
will receive the group-based intervention. In each centre this will require running 
three successive iterations of the programme, recruiting in blocks of around 20. The 
fatigue management programme has been designed for groups of between 6-12 
participants.  
 
Participants will be recruited using a variety of methods; via MS Services/Neurology 
Departments, MS Society newsletters and website, other relevant newsletters, MS 
Research database, MS support groups, General Practitioners. 
 
Recruitment and consent  
Potential participants (identified via secondary or primary care or self-referred) will 
be sent a trial information pack (Key Facts sheet, a set of Participant Information 
Sheets, two screening measures (FSS & APDDS), response slips (interested to hear 
more/decline to participate, plus reasons why) and a prepaid envelope. They will be 
asked to return a reply slip and the two completed screening measures in a prepaid 
envelope to the Local Investigator (LI) if they wish to find out more about the trial, or 
a decline slip, if they would prefer not to receive any further information. Individuals 
who have not responded will be sent a second trial information pack two weeks later 
and a final invitation to participate one month later. 
 
The LI in each centre will telephone those who have expressed an interest in the trial 
and give them an opportunity to ask questions. If, after this discussion, the individual 
still wishes to take part, the LI will undertake a screening using a checklist. After 
screening, participants will be notified via the telephone whether they are eligible or 
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ineligible. Participants who are currently ineligible (e.g. due to medication recently 
started, a planned holiday, having received fatigue advice etc.) but who may fulfil 
eligibility criteria at a later date will be held over to be rescreened (if another iteration 
is scheduled in the centre). Individuals who are ineligible will  be sent a letter 
notifying them of this, along with a booklet produced by the MS Society about MS-
fatigue [54]. 
 
Randomisation 
To ensure good allocation concealment, random allocation will be e-mail-based and 
administered at Poole Hospital by the statistician who will be blinded to the identity 
of participants. Once a block of participants from a centre have provided informed 
consent they will be formally entered onto the trial database and an anonymised list of 
their identification numbers will be sent to the statistician who will randomly allocate 
half to the FMP group and half to the current local practice group. This method 
implies stratification by centre.  
 
Outcome Measures 
The following demographic information will be collected before the start of the trial: 
age, sex, educational attainment, marital status, number of children, length of time 
since diagnosis, disease course, relapse history, employment status, prescribed drugs 
currently taken, co-morbid medical conditions, disability level. 
 
For those randomised to the FMP, outcomes will be measured 1 week prior to the start 
of the programme and 1 month, 4 months and 12 months after the end of the 
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programme. For those randomised to current local practice, outcomes will be sent on 
the same dates as those randomised to the FMP. 
 
Primary Outcome Measures: 
These are all self-reported questionnaire measures and specified a priori.  
There are three primary outcomes: 
 
1. Self-reported fatigue severity 
The Fatigue Assessment Instrument (FAI) [55] is an expanded version of the uni-
dimensional Fatigue Severity Scale (FSS) [51]. The FSS is one of the best known and 
most used fatigue scales. It principally measures the impact of fatigue on specific 
types of functioning. The FAI has four subscales: fatigue severity, situation 
specificity, consequences of fatigue, and responsiveness to rest/sleep. Responses are 
made on a 7-point Likert-type scale. The fatigue severity subscale of the FAI 
corresponds almost exactly to the Fatigue Severity Scale, sharing eight of the original 
nine items along with three additional items. Scores on this subscale are a primary 
outcome. The other subscales are secondary outcomes.  
 
2. Self-reported MS-specific quality of life 
The Multiple Sclerosis Impact Scale (MSIS-29) [56,57] measures the physical (20 
items) and psychological impact (9 items) of MS on day-to-day life. It uses 5-point 
Likert-type scales ranging from ‘not at all’ to ‘extremely’ and is based on quality of 
life in the last two weeks. The total score for the MSIS-29 is a primary outcome 
measure. The physical and psychological subscales will be secondary outcomes. 
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3. Self-reported self-efficacy for managing fatigue 
The Multiple Sclerosis-Fatigue Self-Efficacy (MS-FSE) scale is adapted from the 
Control subscale of the MS Self-Efficacy (MSSE) Scale developed by Schwartz [58]. 
This adapted scale has undergone a preliminary validation in our pilot research. 
 
Secondary outcomes 
Self-reported fatigue 
Three of the subscales from the FAI [55] (namely, situation specificity, consequences 
of fatigue and responsiveness to rest/sleep) along with the total score of the FAI.  
 
Self-reported MS-specific quality of life  
The subscale scores of the MSIS-29 [56,57] for the physical and psychological impact 
of MS.  
 
Self-reported general quality of life 
1. The Medical Outcomes Short-Form Survey version 2 (SF-36v2) [59,60] measures 
eight dimensions: physical functioning, role limitations because of physical health 
problems, bodily pain, general health perceptions, vitality, social functioning, role 
limitations because of emotional problems, and mental health. It generates scores for 
the eight dimensions as well as two summary measures (physical health and mental 
health). It uses Likert-type response scales. This measure will also be used to 
calculate Quality Adjusted Life Years (QALYs) for the economic analysis. 
 
2. The EuroQoL (EQ-5D) [61] is a standardised instrument for use as a measure of 
health outcome. It has been developed by the EuroQoL Group as a simple, generic 
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measure of health status, and is applicable to a wide range of health conditions. The 
EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale 
(EQ VAS) and it allows the derivation of a single index value for health status. The 
EQ-5D descriptive system comprises five dimensions (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression) each rated on three levels (no 
problems, some problems, severe problems). The EQ VAS records the respondent’s 
self-rated health on a vertical, visual analogue scale where the endpoints are labelled 
‘best imaginable health state’ and ‘worst imaginable health state’.  
 
Self-reported mood 
The Hospital Anxiety and Depression Scale (HADS) [62] is a self-report measure 
consisting of an anxiety and a depression subscale. Each subscale consists of 7 items 
with a 4-point Likert-type response scale. 
 
Self-reported fatigue severity 
The Fatigue Symptom Inventory (FSI) [63,64] is a 14-item self-administered multi-
dimensional questionnaire which measures the severity, frequency, and diurnal 
variation of fatigue and its perceived interference on quality of life. Severity is 
measured using four separate items that assess most, least, and average fatigue in the 
past week, as well as current fatigue. Frequency is measured using two separate items 
that assess the number of days in the past week that respondents felt fatigued, as well 
as the portion of the day on average they felt fatigued. Diurnal variation is measured 
using a single item that provides descriptive information about daily patterns of 
fatigue. Perceived interference is measured using seven separate items. 
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Self-reported sleep quality  
These questions have been modified from the MS Clinical Practice Guidelines sleep 
questionnaire [7]. Questions include duration and quality of night-time sleep, factors 
that may prevent or interrupt sleep, and daytime sleeping and sleepiness. 
 
Self-reported resource utilisation 
A resource utilisation questionnaire will be administered at 4- and 12-month follow-up. 
It is adapted from one utilised in a large randomised controlled trial in Parkinson’s 
disease [65], and includes questions about health and social service contacts in the 
preceding 3 months.  
 
Self-reported fatigue management strategies  
To gain deeper insights into the results of the trial, at the 4-month follow-up we will 
administer a semi-structured questionnaire to participants randomised to the FMP. In 
the questionnaire (which draws upon an existing questionnaire [66]) they will be 
asked to describe whether they have tried to make any changes to their lifestyle, 
behaviour, or thinking, as a result of the intervention; whether these changes have 
been made successfully or unsuccessfully, and the reasons why. The information they 
provide will be analysed both quantitatively (for example, number of lifestyle 
changes, number of successes) and qualitatively (identifying emergent themes in the 
responses given [67,68]). In this way, we will be able to look closely at “adherence” 
to the key principles of the intervention, which will help in the interpretation of the 
trial results. 
 
Objective measure of physical activity 
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The activPAL™ accelerometer classifies an individual's free-living activity into 
periods spent lying/sitting, standing and walking [69]. This information can be used to 
estimate daily energy expenditure, and time spent resting. Data will be collected at 
baseline and at 1- and 4-month follow-up. A postal method of administration was 
tested during an earlier research phase. 
 
Self-reported satisfaction 
Participants in the intervention arm will be asked to complete a brief semi-structured 
evaluation questionnaire at the end of each session of the fatigue management 
programme. This questionnaire was used in the pilot phases of the research [45]. 
 
Intervention 
The group-based fatigue manangement intervention [45] is based upon a conceptual 
framework that integrates elements from cognitive behavioural [70], social-cognitive 
[71], energy effectiveness, self-management [72] and self-efficacy [73] theories.  
 
The intervention focuses on the management of fatigue, the most common symptom 
of MS, and is likely to be relevant to many people. However, it is expected that it will 
also provide a framework to help people manage their MS more generally. A 
cognitive behavioural approach that focuses on one symptom is likely to be clearer 
and less overwhelming than one encompassing many aspects, can be achieved in a 
smaller number of sessions, and will be easier to integrate within existing services.  
 
The intervention consists of six sessions held on a weekly basis; the first, 2 hours’ 
duration, and subsequent sessions, 1.75 hours’ duration (each with a 15 minute 
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refreshment break halfway through). It is designed to be run by two health 
professionals with experience of working with people with MS and of group-work 
(such as occupational therapists, nurses, or physiotherapists). This latter feature 
enables the intervention to be incorporated into existing health service structures. The 
intervention will be delivered to groups of 6-12 people. 
  
Participants are encouraged to bring along a “supportive other” to the first session. 
Since the intervention entails participants making lifestyle changes, the involvement 
of a “supportive other” could help to encourage and support them in making such 
changes. Contact between members of the group outside the formal group setting will 
be encouraged, as an additional source of support.  
 
The intervention is manualised and sessions are delivered via PowerPoint. A summary 
of programme content is presented in Table 1. The facilitator manual (~100 pages) 
provides detailed session information, guidance on preparation and delivery, a 
checklist of facilitator objectives and signposts to additional resources. There is also a 
companion participant workbook to reinforce material from the programme. 
Facilitators will be trained at one day orientation workshops and psychological advice 
and debriefing will be available for facilitators throughout the trial.   
 
The aim of the intervention is to help people manage their fatigue by: 
1. Normalising the experience of fatigue 
2. Using their available energy more effectively 
3. Developing “helpful thinking styles” about fatigue 
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Missed sessions 
If participants do not attend a session they will be sent the materials they missed and, 
where possible, the session will be held over the telephone. Participants receiving the 
intervention will continue to have access to services available as part of their usual 
local care. 
 
Control group 
Participants randomised to this arm of the trial will receive current local practice. 
Inevitably, there will be minor variations in the exact composition of what is usually 
provided, both within and between centres; depending on local resources and patient 
need. We consider this minor variation in current local practice to be a strength of the 
trial as it will increase the applicability of the findings to a wider range of centres. 
Individuals who have recently received substantive fatigue management are not 
eligible for the trial (see exclusion criteria).  
 
Results  
Statistical analysis 
We will conduct two sets of statistical analyses. The primary analysis will be an 
intention-to-treat analysis, whereby participants are analysed in the arm of the trial 
they were randomised to, regardless of how many sessions of the programme they 
attend. In order for an intention-to-treat analysis to be conducted, we will endeavour 
to collect outcome measures for everyone (while recognising the right of participants 
to withdraw from the trial at any stage). The secondary analysis will be conducted on 
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a “per protocol” basis. This analysis will exclude participants who attend fewer than 
four sessions of the fatigue management programme.  
 
Data will be analysed primarily using SPSS for Windows. A 5% significance level 
will be used. Outcome measures will be assumed to be interval scaled, and the 
analysis will initially be focused on absolute change in outcome post-intervention 
relative to baseline, and absolute change in outcome at 4- and 12-month follow-up, 
relative to baseline. These change scores, presented separately for the three follow-up 
periods, are being used because we think they are the most clinically useful. They are 
likely to be normally distributed (this assumption will be checked). Change scores 
will be compared between the two groups using the independent samples t-test.  
 
Additional analyses will be conducted to address the following issues: 
 
1. We will adjust for baseline variability/baseline differences between treatment arms. 
For each outcome variable analysed, these would include the baseline measurement 
for that outcome, baseline primary outcome measures, gender, age, marital status, 
education level, type of MS, time since diagnosis, and level of disability.  
 
2. Although participants in the trial have been randomised individually, for those 
randomised to the fatigue management intervention, it is possible that the group-based 
nature of the intervention will result in observations that are clustered. This could 
result in misleading statistical tests [74]. We will assess the extent to which this 
occurs by incorporating clustering into the analysis. 
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3. It is likely that outcome data will be missing for some participants. In the main 
analysis such individuals will be excluded. However, the implied assumption that the 
data are “Missing Completely At Random” might not be correct, potentially leading 
to biased estimates of the effect of the intervention [75]. Two methods will be used to 
assess the extent to which this occurs: Firstly, we will use the “Last Observation 
Carried Forward” imputation method (which assumes no change in outcome when a 
data point is missing). Secondly, we will use a mixed model for repeated 
measurements.  
 
4. Analysing the change in outcome from baseline to each time point will, we believe, 
result in the most clinically useful presentation of results. However, to gain a deeper 
understanding of how outcome measures change over the course of follow-up, we will 
also model all measurement occasions together for each outcome.  
 
5. It is possible that the fatigue management programme might be more effective in 
certain sub-groups of individuals. We will examine these potential effect modifiers by 
testing the relevant “treatment x effect modifier” interaction terms. However, we 
acknowledge that these statistical tests are likely to be underpowered, since this was 
not a specific aim of the study. In these analyses, we will consider study centre, 
baseline fatigue, gender, age, marital status, type of MS, time since diagnosis, and 
level of disability.  
 
These additional analyses will involve the use of a variety of techniques including 
multi-level/mixed models. In addition to these pre-specified analyses, we will also 
conduct further exploratory analyses as suggested by the data.  
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Presentation of the results will follow the Consolidated Standards of Reporting Trials 
(CONSORT) [76,77] guidelines, in such a way that they can be meaningfully 
incorporated into systematic reviews. The design of the trial will help ensure that it is 
graded as high quality in systematic reviews.  
 
Economics evaluation 
The economic burden of MS on the health services, on people with MS, their families 
(and/or carers) and society is high [78]. We recognise this as an important issue, and 
one that should be considered in the context of clinical trials. This is especially 
relevant in the United Kingdom NHS, where health policy decision makers (e.g. 
National Institute for Health and Clinical Excellence (NICE)) are interested in both 
the clinical value and cost-effectiveness of interventions. Therefore, alongside the 
proposed clinical trial, an economic evaluation will be undertaken to assess the 
incremental costs, incremental benefits, and the resulting cost-effectiveness of 
introducing a group-based cognitive behavioural approach to managing fatigue in 
people with MS, compared with current local practice (excluding the intervention). 
 
It is anticipated that the primary economic endpoint will involve a clinically 
significant improvement in fatigue (e.g. cost per unit change in the fatigue outcome 
measure). Thereafter, the economic evaluation will estimate the cost per unit change 
in quality of life (e.g. MSIS-29, SF-36), and it will estimate the cost per Quality 
Adjusted Life Year (QALY) associated with the introduction of the group-based 
cognitive behavioural approach, as a more meaningful and policy relevant outcome. 
QALY estimates will be based on individual patient level data collected in the trial 
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using the SF-36 and the EQ-5D. The economic assessment will explore the longer 
term consequences of improvements identified (expected) in fatigue and quality of 
life, modelling outcomes over time, where possible and appropriate, on the basis of 
the findings from the proposed trial. Where modelling of costs and consequences is 
undertaken, it will follow guidelines for good practice reported by Phillips and 
colleagues [79]. 
 
Perspective: A broad perspective to the measurement of costs and outcomes will be 
adopted, and results will be presented separately from the perspective of the NHS and 
personal social services (i.e. Third Party Payer), and from a broader societal 
perspective.  
 
Data Collection: Trial data will be used to consider the relative effectiveness of the 
intervention versus comparator, and primary and secondary outcome measures have 
been described above. Patient level data will be collected within the trial both pre- and 
post-intervention, and at 4- and 12-month follow-up for those in the fatigue 
management arm of the trial and equivalent time points post-randomisation for those 
receiving current local practice. The primary economic analysis of outcomes will be 
between baseline and 4-month follow-up, although analysis using the shorter time 
horizon, and other longer term modelled outcomes will also be presented.  
 
Resource use data will be collected over the 4-month follow-up period and will 
primarily comprise the direct delivery of the group-based cognitive behavioural 
approach (e.g. staff time, related consumables, and any travel costs for the health 
professional). Record forms will be used by staff delivering the intervention to 
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identify staff time used, and the main categories of staff time (e.g. delivery of 
sessions, preparation, setting-up) and semi-structured interviews will be held with 
each of the Service Providers (centres) to estimate the broader resource use associated 
with delivery of the intervention.  
 
Further data on NHS and personal social services resource use (e.g. related 
hospitalisation, Accident and Emergency Department visits, and General Practitioner 
visits) and information on carer time will be gathered using a simple patient self-
completion questionnaire (completed at 4- and 12- month follow-up), and differences 
between groups will be investigated and reported as part of the economic analysis. 
 
Cost Analysis: Cost analysis will estimate direct costs (i.e. those costs directly 
associated with the delivery of the intervention and the related follow-up of patients), 
using resource use data collected within the RCT, and staff and unit cost data from 
credible sources (national statistics and data from participating centres e.g. salary 
scales). Other costs will be determined using the data from the patient questionnaire 
and appropriate sources for unit cost data (e.g. Personal Social Services Research Unit 
(PSSRU), University of Kent at Canterbury, NHS Reference costs, local NHS Trust 
cost data). A mean net cost per patient in each arm of the trial and an incremental cost 
per patient, with associated measures of variance, will be calculated. Statistical 
analysis will characterise any uncertainty, and subgroup analysis (e.g. by disease 
severity) will be presented. All sources of cost data will be specified and all estimates 
will be transparent. Sensitivity analyses will be undertaken to address uncertainty 
within the unit cost estimates. 
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Where costs and benefits are considered beyond a 12-month time period, the 
evaluation will follow the present National Health Service (NHS)/Department of 
Health convention and discount future costs and future benefits at 3.5% per year. 
Analysis will also report non-discounted findings and findings where costs and 
benefits are subject to a range of discounted rates. 
 
Sensitivity Analyses: Uncertainty in data estimates/assumptions will be subject to 
detailed sensitivity analysis, using plausible data ranges, where results indicate this to 
be appropriate (e.g. variations in staff grades and staff costs, variations in the 
estimates for NHS resource use and the relevant unit costs). Where data point 
estimates are not subject to sensitivity analysis, reasons for this will be given. Where 
undertaken, and as appropriate, sensitivity analysis will comprise one-way analysis, 
multi-way analysis, scenario analysis, and where modelling is undertaken, it will 
include probabilistic sensitivity analysis. 
 
Serious adverse events 
Adverse events will be defined according to standard clinical trial definitions and 
serious adverse events will be reported to the Multi-centre Research Ethics 
Committee (MREC) within 15 days by the Chief Investigator.  
 
Data management 
The trial data will be entered onto an SPSS spreadsheet by an administrator. A 
random 10% sample of the data will be checked for accuracy. 
 
Participant withdrawal of consent to research follow-up 
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If a participant withdraws consent to be included in research follow-up during the 
trial, the local investigator (LI) will be informed and will contact the participant. 
Provided the participant is willing to give a reason, the LI will find out why (s)he 
wishes to withdraw from the research follow-up. The LI will also determine whether 
the participant has given permission to retain data collected before withdrawal for use 
at final analysis, or whether this information should be destroyed. No data will be 
used in the analysis without a participant’s consent.  
 
Discussion  
This is a pragmatic trial aimed at answering the question of whether introducing the 
intervention into a service has a significant impact on fatigue, self-efficacy, and 
quality of life, and whether it represents value for money to the NHS. These are the 
most important questions from a health service and patient perspective.  
 
A strength of this trial is the fact that the mixed methodology pilot work (intervention 
development and process and preliminary evaluation) underpinning the trial has been 
rigorously conducted and documented following the Medical Research Council 
guidance for the development of a complex intervention [46]. The intervention is fully 
manualised and supported by training and PowerPoint materials meaning that it can 
be easily replicated in a standardised form. The multi-centre nature of the trial gives 
the opportunity to test whether the intervention transfers successfully to other 
geographic areas. The intervention has been developed so that it can be delivered by 
those already routinely involved in the care of people with MS. Thus, if found to be 
beneficial, it could be readily incorporated into existing services, facilitating the 
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integration of psychology-based approaches into patient care. The 12-month follow- 
up period offers the opportunity to explore and assess longer term effects. 
 
Service users have been involved throughout the research process, from the pilot work 
through to the RCT (as lay grant application and document reviewers, focus group 
participants, trial participants and as members of the steering group). Participants 
randomised to the intervention arm will have an opportunity to provide satisfaction 
and process feedback via session evaluation questionnaires and a semi-structured 
questionnaire administered at the second follow-up. 
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Table 1 - Summary of content of the Fatigue Management Programme  
Session Title Content Homework 
1 
 
 
What is MS-related fatigue? 
 
General introduction; expectations; 
icebreaker (quiz); types of fatigue; 
contributory factors, conceptual    
model of fatigue in MS 
Activity/fatigue diary 
2 Opening an “energy 
account” 
 
Rest - functions; barriers; relaxation 
types and techniques; diaphragmatic 
breathing exercise; sleep hygiene 
Rest/activity/sleep 
planner 
3 Budgeting energy & 
smartening up goals 
 
Types of activity; balancing activity & 
rest; moderating activity using the 
toolbox; goal-setting 
Goal-setting exercise 
4 The stress response; 
Introducing the cognitive 
behavioural model 
The stress response (fight-or-flight); 
ways of coping with stress; 
introducing the cognitive behavioural 
model 
‘Unhelpful thoughts 
related to fatigue’ diary 
5 Putting unhelpful thoughts 
on trial 
 
Unhelpful thought patterns related to 
fatigue; challenging unhelpful 
thoughts; levels of belief 
Thought challenge 
sheet 
6 Recapping & taking the 
programme forward 
Revisiting expectations; group activity 
to revisit themes of the programme; 
rationale of ‘Keeping on Track’ 
planner  
‘Keeping on Track’ 
planner 
 
 
Figure 1 - Flowchart of trial design 
  
 
 
 
 
 
 
 
 
 
 
180 eligible,  
consenting  
participants 
Randomisation 
(stratified by centre) 
Baseline Assessment - 5 weeks post-randomisation 
[Equivalent to 1 week pre-intervention in FMP arm] 
Follow-up assessment (2) - 7 months post-randomisation 
[Equivalent to 4 months post-intervention in FMP arm] 
Follow-up assessment (1) - 4 months post-randomisation 
[Equivalent to 1 month post-intervention in FMP arm] 
Fatigue 
Management 
Programme 
Current 
Local  
Practice 
 
Follow-up assessment (3) - 15 months post-randomisation 
[Equivalent to 12 months post-intervention in FMP arm] 
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